Top-line results are expected in the second quarter of 2017 The randomized, double-blind, placebo-controlled Phase III study ...
BERKELEY, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical ...
Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], ...
